Pulmonary Hypertension: A Common Complication of Left Heart Disease

Advances in Pulmonary Hypertension

¹ 

关键词: Cardiology;    Psychosocial Issues;    Lifestyle Issues;    Social Work;    WHO Group 1- Pulmonary Arterial Hypertension;    WHO Group 2- PH owing to left heart disease (left heart failure);    WHO Group 3- Pulmonary hypertension owing to lung disease;    /or hypoxia;    PH Medications;    Right Heart Failure;    Cardiac MRI;    Nuclear Scan (Ventilation/Perfusion Scan or V/Q scan);    Surgical Interventions;    Mechanical Assist Devices;    Anatomy;    Physiology/Pathophysiology;    symptoms;    Idiopathic (Primary pulmonary hypertension);    Systolic dysfunction;    diastolic dysfunction;    Sleep Apnea;    Oral therapy;    IV therapy;    Inhaled therapy;    Phosphodiesterase Inhibitors (PDE-5 Inhibitors);    Endothelin Receptor Antagonists;    nitric oxide;    Diuretics;    Inotropes;    RV Size;    Indicators of diastolic dysfunction;    Non-invasive estimate of PVR;    Pulmonary vascular resistance;    pulmonary artery pressure;    Cardiac Output;    Cardiac Index;    Fick;    Thermodilution;    exercise hemodynamic testing;    Preserved ejection fraction;    endothelial proliferation;    endothelial dysfunction;    tricuspid regurgitation;    dyspnea;    edema;    patient-reported outcomes;    clinical trial endpoints;    Angiogram;    Classification;    Epidemiology;   

DOI  :  

学科分类：医学（综合）

来源: Pulmonary Hypertension Association

【 摘 要 】

With the significant medical advances in the treatment of PAH, transplantation should be reserved for those patients who have failed pharmacologic therapy. In this subset of patients who do not respond, deteriorate on, or do not tolerate pulmonary vasodilators, significant improvement in hemodynamics, NYHA functional class, actuarial survival, and quality of life has been demonstrated with isolated lung transplantation. Candidate selection and timing of referral to transplant centers is critical for ultimate success, particularly with current allocation protocols that do not take into account the severity of illness. Though long-term success is tempered by chronic allograft dysfunction and infection, significant improvements in outcomes have established lung transplantation for PAH as an efficacious and life-prolonging treatment.

【 授权许可】

All Rights reserved